NFKB1 and dry eye syndrome: Particularly, treatment with ALA in cultures of corneal epithelial cells and when it is topically applied to a dry eye animal model has anti-inflammatory activity, decreasing the release and expression of inflammatory factors (TNF-a, IL-6, IL-1β, and IL-8) regulated by the NF-κB pathway [34,35].